Elevation Oncology ends EO-3021 development after Phase 1 results, shifts focus to EO-1022, and plans a major workforce ...

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Scientists have discovered that aspirin may prevent cancer metastasis by reducing TXA2 levels, which suppress T cells.

In recently published work from Air Force Medical University, analysis of tumor tissues isolated from different patient-derived xenografts revealed significantly increased expression of FXYD5 in the ...

[6] Jin Li et al., HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind ...

NCT03615326), which included 698 patients with HER2-positive advanced gastric or GEJ adenocarcinoma not previously treated with systemic therapy for metastatic disease; 85% (n=594) of patients had ...

SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the ...